Targeting purinergic receptors to attenuate inflammation of dry eye.


Journal

Purinergic signalling
ISSN: 1573-9546
Titre abrégé: Purinergic Signal
Pays: Netherlands
ID NLM: 101250499

Informations de publication

Date de publication:
03 2023
Historique:
received: 31 10 2021
accepted: 04 02 2022
pubmed: 27 2 2022
medline: 8 3 2023
entrez: 26 2 2022
Statut: ppublish

Résumé

Inflammation is one of the potential factors to cause the damage of ocular surface in dry eye disease (DED). Increasing evidence indicated that purinergic A

Identifiants

pubmed: 35218451
doi: 10.1007/s11302-022-09851-9
pii: 10.1007/s11302-022-09851-9
pmc: PMC9984584
doi:

Substances chimiques

Receptors, Purinergic 0
Receptors, Purinergic P1 0
Cytokines 0
Adenosine Triphosphate 8L70Q75FXE
Receptors, Purinergic P2X7 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-206

Informations de copyright

© 2022. The Author(s).

Références

Cornea. 2004 Nov;23(8):784-92
pubmed: 15502479
Signal Transduct Target Ther. 2021 Apr 28;6(1):162
pubmed: 33907179
J Neuroimmunol. 2013 Nov 15;264(1-2):54-64
pubmed: 24090652
Med Chem Res. 2021;30(2):353-370
pubmed: 33519168
Mol Pain. 2010 Apr 15;6:21
pubmed: 20398327
Vet J. 2014 Oct;202(1):48-52
pubmed: 25178686
Front Pharmacol. 2017 Sep 25;8:661
pubmed: 28993732
Cell Immunol. 2009;258(2):115-22
pubmed: 19426966
Br J Pharmacol. 1998 Sep;125(2):379-87
pubmed: 9786512
J Immunol. 2019 Feb 1;202(3):883-898
pubmed: 30598517
Curr Opin Allergy Clin Immunol. 2008 Oct;8(5):477-83
pubmed: 18769205
J Gastroenterol Hepatol. 2017 Jul;32(7):1341-1347
pubmed: 27977904
Pharmacol Rev. 2013 Dec 11;66(1):80-101
pubmed: 24335193
PLoS One. 2011;6(12):e28541
pubmed: 22163032
Eur J Pharmacol. 2007 Jun 14;564(1-3):219-25
pubmed: 17382926
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2561-9
pubmed: 17525185
Clin Exp Rheumatol. 2006 Jul-Aug;24(4):400-6
pubmed: 16956430
Front Cell Dev Biol. 2021 Oct 14;9:737426
pubmed: 34722519
Ophthalmology. 2010 Jul;117(7):1287-93
pubmed: 20304499
Front Cell Neurosci. 2019 Mar 28;13:124
pubmed: 30983976
J Neuroinflammation. 2019 Apr 4;16(1):71
pubmed: 30947729
Front Cell Neurosci. 2014 Sep 01;8:260
pubmed: 25225473
PLoS One. 2016 Oct 27;11(10):e0165653
pubmed: 27788256
Exp Eye Res. 2003 Jul;77(1):77-84
pubmed: 12823990
J Physiol. 2007 Oct 1;584(Pt 1):245-59
pubmed: 17656429
Bioorg Med Chem. 2014 Jan 1;22(1):54-88
pubmed: 24314880
Ophthalmic Res. 2008 Oct;40(6):315-21
pubmed: 18688174
Clin Ophthalmol. 2019 Feb 01;13:225-232
pubmed: 30774303
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4293-301
pubmed: 15557435
Ophthalmic Res. 2004 Mar-Apr;36(2):89-93
pubmed: 15017104
J Med Chem. 2012 Jan 12;55(1):342-56
pubmed: 22142423
Drug Discov Today. 2016 Feb;21(2):288-98
pubmed: 26743596
Ocul Surf. 2010 Oct;8(4):185-92
pubmed: 20964981
Invest Ophthalmol Vis Sci. 1999 Jan;40(1):28-34
pubmed: 9888423
Front Pharmacol. 2021 Jun 15;12:654445
pubmed: 34211393
Hear Res. 2005 Nov;209(1-2):24-31
pubmed: 16139976
J Pharmacol Exp Ther. 2013 Jun;345(3):331-41
pubmed: 23504005
Brain Behav Immun. 2010 Oct;24(7):1176-89
pubmed: 20554014
Purinergic Signal. 2004 Dec;1(1):83-90
pubmed: 18404404
Drug News Perspect. 2008 Apr;21(3):166-76
pubmed: 18560615
Arthritis Res Ther. 2006;8(1):R33
pubmed: 16507132
Surv Ophthalmol. 2009 May-Jun;54(3):321-38
pubmed: 19422961
J Med Chem. 2014 Oct 9;57(19):7874-87
pubmed: 24946140
Front Pharmacol. 2020 Jan 16;10:1558
pubmed: 32009961
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1285-95
pubmed: 22323486
Arq Bras Oftalmol. 2008 Nov-Dec;71(6 Suppl):89-95
pubmed: 19274418
J Intern Med. 2013 Nov;274(5):480-9
pubmed: 23906036
J Pharmacol Exp Ther. 2002 Jan;300(1):291-7
pubmed: 11752128
Med Res Rev. 2018 Jul;38(4):1031-1072
pubmed: 28682469
ACS Chem Neurosci. 2020 Dec 16;11(24):4387-4397
pubmed: 33284579
Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4384-91
pubmed: 18502993
Am J Pathol. 2005 Jan;166(1):61-71
pubmed: 15632000
Ophthalmology. 2000 Oct;107(10):1841-9
pubmed: 11013183
J Inflamm Res. 2021 Feb 15;14:367-378
pubmed: 33623409
Int J Mol Sci. 2021 Sep 30;22(19):
pubmed: 34638992
Pharmacol Ther. 2008 Jul;119(1):55-73
pubmed: 18562011
Cells. 2020 Jul 21;9(7):
pubmed: 32708189
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H81-7
pubmed: 20400685
PLoS One. 2013 Sep 10;8(9):e74010
pubmed: 24040145
Ocul Surf. 2017 Jul;15(3):438-510
pubmed: 28736340
Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5108-5115
pubmed: 30372737
Biochem Biophys Res Commun. 2013 Jul 5;436(3):355-61
pubmed: 23685153
Exp Eye Res. 2014 Oct;127:270-9
pubmed: 25151301

Auteurs

Jia-Ning Wang (JN)

Eye Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Hua Fan (H)

Eye Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Jian-Tao Song (JT)

Eye Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Jangts@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH